If you have been exploring medically supported weight loss, you have likely come across two names: semaglutide (GLP‑1) and tirzepatide (GLP-1/GIP). Both belong to a class of injectable medications that mimic natural hormones involved in appetite regulation and blood sugar control.
Compounded versions of these medications have made them more accessible and affordable for many patients who may lack insurance coverage or need a personalized formulation. Understanding how these two options compare, including tirzepatide’s unique GLP-1/GIP dual receptor action, can help you have a more informed conversation with your healthcare provider.
This article breaks down the differences between compounded tirzepatide and compounded semaglutide, including how they work, the benefits each may offer, and their side effects.
Semaglutide is a GLP-1 (glucagon-like peptide-1) receptor agonist. It works by mimicking the GLP-1 hormone that your body naturally produces after eating. This hormone plays a role in stimulating insulin release, slowing the rate at which food moves through your stomach, and signaling to your brain that you feel full. By activating these pathways, semaglutide helps reduce appetite and calorie intake over time.
Brand-name versions of semaglutide include Wegovy (approved for weight management) and Ozempic (approved for type 2 diabetes). Compounded semaglutide is prepared by licensed compounding pharmacies and offers the same active ingredient, often with the option for personalized dosing or supportive additives like Vitamin B6 or Vitamin B-12.
It is administered as a once-weekly subcutaneous injection, typically starting at 0.25 mg and gradually increasing based on your provider’s guidance.
Tirzepatide takes a different approach. It is a dual GLP-1/GIP (glucose-dependent insulinotropic polypeptide) receptor agonist, meaning it activates two distinct hormone pathways instead of one. In addition to the appetite-regulating effects of GLP-1, the GIP component helps improve insulin sensitivity and may support fat metabolism. This dual mechanism is the primary pharmacological distinction between tirzepatide and semaglutide.
Brand-name tirzepatide is sold as Zepbound (for weight management) and Mounjaro (for type 2 diabetes). Like compounded semaglutide, the compounded version is formulated by state-licensed pharmacies and offers a more affordable alternative.
Compounded tirzepatide is also injected once weekly, with starting doses typically at 2.5 mg and the potential to increase up to 15 mg under medical supervision.
The most notable difference is the number of hormone receptors each medication targets. Semaglutide activates the GLP-1 receptor alone, which supports appetite control and blood sugar regulation.
Tirzepatide activates both the GLP-1 and GIP receptors, which may provide an added layer of metabolic benefit. The GIP pathway is thought to play a role in how the body processes and stores fat, and this dual action is what sets tirzepatide apart as a GLP-1/GIP agonist.
Both medications have demonstrated meaningful clinical results. A 2024 cohort study published in JAMA Internal Medicine compared over 18,000 propensity-matched adults receiving tirzepatide or semaglutide. Patients on tirzepatide were significantly more likely to reach weight loss milestones of 5%, 10%, and 15% of their body weight.
At 12 months, patients on tirzepatide had an additional 6.9% weight reduction compared to those on semaglutide. Individual results will always vary based on dosage, adherence, lifestyle factors, and overall health.
Both medications follow a gradual dose-escalation schedule to help minimize side effects. Semaglutide typically begins at 0.25 mg per week and can increase up to 2.4 mg.
Tirzepatide starts at 2.5 mg per week and can be titrated up to 15 mg. Your provider will adjust dosing based on how your body responds, and compounding allows for additional customization that may not be possible with pre-filled brand-name pens.
Semaglutide and tirzepatide share a similar side effect profile because both slow gastric emptying. The most commonly reported effects include nausea, vomiting, diarrhea, constipation, and decreased appetite. For most patients, these GI symptoms are mild to moderate and tend to improve during the first few weeks as the body adjusts. Gradual dose increases are the primary strategy providers use to reduce discomfort early on.
A systematic review and meta-analysis published in Annals of Saudi Medicine analyzed 13 randomized controlled trials and found that gastrointestinal side effects were common with both medications compared to placebo. The review also noted that semaglutide carried a higher association with gallbladder-related events, while neither medication showed a statistically significant increase in pancreatic or liver-related adverse events.
Rare but serious side effects for both medications include a boxed warning about thyroid C-cell tumors observed in animal studies. Patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 should not use either medication. This is one of many reasons why medical screening and ongoing provider oversight are essential throughout treatment.
The right medication depends on your individual health profile and goals.
Compounded semaglutide may be a good starting point for patients new to GLP-1 therapy who want to begin with a well-established single-receptor option. It has a long track record of clinical use and remains one of the most widely prescribed GLP-1 medications.
Compounded tirzepatide, with its dual GLP-1/GIP mechanism, may appeal to patients looking for a medication that targets multiple metabolic pathways. Research suggests it can lead to greater weight loss in many patients, and some providers may consider it for patients exploring additional metabolic support after discussing semaglutide results.
Ultimately, a licensed healthcare provider is the best person to help determine which option aligns with your medical history, health conditions, and weight loss goals.
Yes, switching is possible with medical guidance. Your provider will typically start you on a lower dose of the new medication to ensure your body adjusts safely. It is not a direct dose-for-dose transfer, so provider involvement is essential.
Most patients begin noticing changes within the first few weeks of treatment, though meaningful weight loss often becomes more apparent after two to three months. Results vary depending on dosing, lifestyle, and individual response.
Compounded GLP-1 medications are not FDA-approved for safety, efficacy, or quality in the same way brand-name drugs are. They are prepared by state-licensed or FDA-registered compounding pharmacies and must use ingredients from FDA-licensed facilities.
No. Compounded GLP-1 medications are typically purchased out of pocket. Providers offer transparent pricing that includes consultations, medication, and shipping without requiring insurance.
Copyright © 2026 Hydrate and Heal LLC - All Rights Reserved.
All sales are final and non-refundable, including sign-on fees. All treatments/prescriptions are prepaid and cannot be returned or exchanged, refunded, credited, or transferred. Monthly Maintenance and/or Memberships must be canceled within 10 days before a new charge, or it will not be refunded.
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.